Closely-watched start-up Caribou Biosciences announced 02 April that it has brought in $11m in Series A round financing through a group of deep-pocketed investors, including European pharma giant Novartis.
The biotech is a developer of CRISPR-cas9 technology, a type of gene editing that has the oncology world abuzz.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?